Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Gold Trust (IAU) vs Smith & Nephew plc (SNN) Price & Performance

iShares Gold TrustTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

iShares Gold Trust vs Smith & Nephew plc — how do they compare? iShares Gold Trust trades at $82.74, while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while iShares Gold Trust pays none, and iShares Gold Trust is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.

IAUSNN
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$101.57$38.70
52-Week Low
$62.49$28.73
Market Cap
$12.54B
Enterprise Value
$15.57B
Dividend Yield
2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Gold Trust

IAU, the iShares Gold Trust ETF, trades at $82.98 with a 0.57% daily gain amid bullish technical signals from moving averages. The ETF benefits from gold's recent momentum as spot gold reached two-month highs above $4,430/oz following cooling CPI data. While oscillators show bearish signals with RSI at overbought levels, institutional interest remains strong with Deane Retirement Strategies increasing its stake by 36.5% in the latest quarter.

Outlook remains positive as gold gains support from inflation dynamics, geopolitical tensions, and central bank buying. Key risks include potential Fed policy shifts and dollar strength. The 0.25% expense ratio makes IAU attractive for conservative investors seeking gold exposure with lower volatility compared to mining stocks.

Smith & Nephew plc

SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.

The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.

Returns comparison

Trailing returns across standard periods

About iShares Gold Trust

IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.

Read more on IAU

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN